Tadahiro Kuribayashi, Kadoaki Ohashi, Kazuya Nishii, Kiichiro Ninomiya, Yukari Tsubata, Nobuhisa Ishikawa, Masahiro Kodani, Nobuhiro Kanaji, Masahiro Yamasaki, Kazunori Fujitaka, et al. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study. Journal of cancer research and clinical oncology. 2024. 150. 2. 89-89
Naofumi Hara, Eiki Ichihara, Hirohisa Kano, Chihiro Ando, Ayako Morita, Tatsuya Nishi, Sachi Okawa, Takamasa Nakasuka, Atsuko Hirabae, Masaya Abe, et al. CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. Translational lung cancer research. 2023. 12. 10. 2098-2112
Takashi Ninomiya, Nobuhisa Ishikawa, Toshiyuki Kozuki, Shoichi Kuyama, Koji Inoue, Toshihide Yokoyama, Nobuhiro Kanaji, Masayuki Yasugi, Takuo Shibayama, Keisuke Aoe, et al. A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations. Lung cancer (Amsterdam, Netherlands). 2023. 184. 107349-107349
Chihiro Ando, Eiki Ichihara, Tatsuya Nishi, Ayako Morita, Naofumi Hara, Kenji Takada, Takamasa Nakasuka, Hiromi Watanabe, Hirohisa Kano, Kazuya Nishii, et al. Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer. Cancer science. 2023
Takaaki Tanaka, Masataka Taoka, Go Makimoto, Kiichiro Ninomiya, Hisao Higo, Masanori Fujii, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, et al. Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer: A Case Report. Internal medicine (Tokyo, Japan). 2023
Nobuaki Ochi, Eiki Ichihara, Nagio Takigawa, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Naohiro Oda, et al. Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression. European journal of cancer (Oxford, England : 1990). 2021. 157. 523-524